Bacterial Infections, Bacterial Vaginosis, Bacterial Vaginosis | Vaginal | Microbiology, Vaginal Infection
Conditions
Brief summary
This study will investigate the effects of PreforPro® (prebiotic and bacteriophages (LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae, and LL12-Myoviridae, greater \> 6.7 X 107 PFU/gram) on bacterial vaginosis.
Detailed description
This is a double-blinded, placebo controlled study. Each study participant will be in the study for 90 days. During the first 28 days the participants will not take study product, and will collect samples for the study in order to act as their own controls. On day 29, participants will be randomized to intervention with either PreforPro® or placebo, which they will take once daily for the remaining 62 days. There will be a total of 5 study visits during which samples will be collected, a Quality of Life questionnaire will be completed at baseline and end of study visit. Samples for the study are: vaginal swab, faecal sample, urine sample.
Interventions
DRUGPreforpro
Preforpro will be investigated to improve vaginal health in women with BV.
OTHERPlacebo
Placebo capsules manufactured to look like Preforpro capsules
Sponsors
Deerland Enzymes
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
St. Joseph's Health Care London
Jeremy Burton
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
Neither participants nor study team will know which product the participants have been assigned. Unblinding can be requested from the pharmacy if necessary.
Intervention model description
Double-blinded, randomized, placebo controlled study
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Female * 18-45 years old premenopausal (period within 6 months) * Nugent score of 4-6 (intermediate) or 7-10 (BV) * Have an ability to collect a clean urine sample * Prescription and over the counter medication unchanged for \> 30 days prior to the study. -Participants who are taking medications as needed (PRN) may be included if they began PRN usage \>30 days prior to baseline * Sexually active status of the participants can be either active or inactive * Participants must agree to use a medically approved method of birth control (e.g. hormonal contraceptives, intrauterine devices, vasectomy/tubal ligation, barrier methods and double-barrier method) and must have negative pregnancy test results at screening and baseline
Exclusion criteria
* Faecal incontinence * History of urinary fistula, bladder or kidney stones, interstitial cystitis, or cystoscopic abnormalities that could be malignant * Neurogenic bladder * A history of currently undergoing immunosuppressive drug therapy, chemotherapy, or radiation therapy * Antibiotic and/or anti-fungal medication used within the last four weeks * Oral probiotic supplement use within 2 weeks prior the study excluding yogurt * Drug abuse * Uncontrolled psychological disorders
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To change Nugent score in women with intermediate grade or BV | 3 months | Vaginal swab is collected to determine the Nugent score, which is a The Nugent Score is a gram stain scoring system for vaginal swabs to diagnose bacterial vaginosis. Nugent scores between 7-10 is the standard diagnosis of BV and indicative of the absence of lactobacilli and a relative predominance of G. vaginalis and Mobiluncus spp. A Nugent score of 4-6 is indicative of intermediate BV. A Nugent score ≤ 3 means there is no BV. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Determine whether the bacteriophage can translocate from the gastrointestinal system to genitourinary system. | 3 months | Urine will be analyzed to determine the amount of antibiotic resistant genes by reverse transcriptase-quantitative polymerase chain reaction (qPCR). The Faecal sample will also be analyzed to determine bacteriophage counts by qPCR. These two tests will tell us if the bacteriophage was able to translocate between the two systems. |
| Determine if the microbiota in the gut and urinary system change | 3 months | To determine this outcome the study team will test quantify and capture E. coli isolates from a urine sample. MSU microbiota analysis will be performed on the sample, and bacteriophage counts will be determined by qPCR. |
| Determine change in vaginal cell exfoliation. | 3 months | Vaginal swab is collected to determine the amount of epithelial cell exfoliation. |
| Determine whether probiotics can translocate from the gastrointestinal system to genitourinary system. | 3 months | MSU microbiota analysis will be performed on the urine and faecal sample to determine the species present in both samples. |
| Determine change in urogenital ATP levels. | 3 months | Urine sample will be collected to quantify urogenital ATP level. A luminescent assay kit (BacTiter-Glo microbial cell viability assay; Promega, WI) will be used to quantify the amount of ATP. The Synergy H4 hybrid multimode microplate reader will be used to quantify the amount of ATP. |
Contacts
Primary ContactJermy Burton, PhD
Backup ContactAlexandria R Agudelo, MLA
Outcome results
None listed